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Abstract
Background: We have previously shown that the grape bioactive compound resveratrol (RSV) potentiates grape
seed extract (GSE)-induced colon cancer cell apoptosis at physiologically relevant concentrations. However, RSV-GSE
combination efficacy against colon cancer stem cells (CSCs), which play a key role in chemotherapy and radiation
resistance, is not known.
Methods: We tested the anti-cancer efficacy of the RSV-GSE against colon CSCs using isolated human colon CSCs
in vitro and an azoxymethane-induced mouse model of colon carcinogenesis in vivo.
Results: RSV-GSE suppressed tumor incidence similar to sulindac, without any gastrointestinal toxicity. Additionally,
RSV-GSE treatment reduced the number of crypts containing cells with nuclear β-catenin (an indicator of colon
CSCs) via induction of apoptosis. In vitro, RSV-GSE suppressed - proliferation, sphere formation, nuclear translocation
of β-catenin (a critical regulator of CSC proliferation) similar to sulindac in isolated human colon CSCs. RSV-GSE, but
not sulindac, suppressed downstream protein levels of Wnt/β-catenin pathway, c-Myc and cyclin D1. RSV-GSE also
induced mitochondrial-mediated apoptosis in colon CSCs characterized by elevated p53, Bax/Bcl-2 ratio and
cleaved PARP. Furthermore, shRNA-mediated knockdown of p53, a tumor suppressor gene, in colon CSCs did not
alter efficacy of RSV-GSE.
Conclusion: The suppression of Wnt/β-catenin signaling and elevated mitochondrial-mediated apoptosis in colon
CSCs support potential clinical testing/application of grape bioactives for colon cancer prevention and/or therapy.
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Background
Colorectal cancer is the third most common cancer
among both men and women in the United States. It is
also the second most common cause of cancer-related
deaths in men and women combined [1]. With regular
screening, colon cancer can be detected early, when
treatment is most effective; however, in the majority of
cases colon cancer is detected late. Over 95 % of colon
cancer cases are considered sporadic thus placing
environmental factors as the major cause [1]. The most
important environmental factors among them are diet
and lifestyle. The highest incidence rates of colon cancer
are in developed nations including the U.S. [2]. Diets
rich in refined starch, sugar, and saturated and trans-
fatty acids but poor in fruits, vegetables and whole grains
(prevalent in developed nations), have been shown to be
closely associated with an increased risk of colon cancer
[2–4]. A meta-analysis of case–control studies suggests
that fruit consumption was associated with a 13 % de-
crease in colon cancer risk. The benefits from consum-
ing a diet rich in fruits and vegetables could be
attributed to the plethora of bioactive compounds
present in them [5].
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Grapes are consumed around the world and are a rich
source of many bioactive compounds. Red grapes are
rich in resveratrol (RSV), a stilbene that has shown anti-
cancer properties in a variety of models, including
human studies [6]. We previously reported that RSV
suppressed proliferation and induced apoptosis via p53
activation in HT-29 and SW-480 human colon cancer
cell lines, however, it was effective only at higher con-
centrations (75–100 μM) [7]. Grape seed extract (GSE)
is a popular dietary supplement rich in proanthocyani-
dins and has been reported to have anti-colon cancer
properties in a variety of in vitro and in vivo models [8].
As bioactive compounds exist in a complex mixture in
fruits and vegetables, laboratory assessment of their
biological activity in combination is more relevant to hu-
man exposure. In addition, because these compounds
have pleiotropic effects, there is the potential that they
will exert additive or synergistic chemopreventive ac-
tions. A recent study that compared GSE induced anti-
cancer effects to the effects of its individual components
found that GSE was more potent in growth inhibition
compared to its individual constituents epigallocatechin,
procyanidins and their association [9]. Our previous
studies also support this notion, as we demonstrated
using a well-established combination index method that
a RSV (~25 μM) and GSE (35–50 μg/ml) mixture was
potent in suppressing proliferation and elevating apop-
tosis in the HCT-116 human colon cancer cell line at
lower concentrations compared to RSV or GSE alone
[10, 11]. Combination index methods is based on the
classic isobologram equation CI = D1/d1 + D2/d2. D1
and D2 are the doses of RSV and GSE respectively in the
combination system where as d1 and d2 are the doses of
RSV and GSE alone for the same fractional inhibition,
respectively. In addition, RSV potentiated GSE-induced
p53-dependent apoptosis via mitochondrial apoptotic
signaling, and demonstrated specificity to cancer cells,
as it was non-toxic in the normal colonic epithelial cell
line CRL-1831 [10]. Our preliminary results led us to
believe that a combinatorial approach towards colon
cancer chemoprevention using bioactive compounds
is a feasible strategy.
Historically, colon tumorigenesis has been viewed as a
stochastic model where wide populations of abnormal
colonocytes have an equal propensity to initiate tumor
growth [12]. However, the cancer stem cell (CSC) theory
suggests that most, if not all, cancerous tumors are
driven by CSCs, probably through dysregulation of self-
renewal pathways [13]. CSCs are capable of self-renewal,
cellular differentiation, and maintain their stem cell-like
characteristics even after invasion and metastasis [14].
Furthermore, they are resistant to standard therapies
and thus are thought to be responsible for cancer relapse.
The Wnt/β-catenin signaling pathway plays a critical role
in maintenance of stemness, and survival/proliferation of
CSCs [15], and as such, targeting the Wnt/β-catenin sig-
naling is a good strategy for cancer prevention. Aberrant
Wnt signaling in colon cancer is typically followed by mu-
tation in the K-ras gene and loss of the tumor suppressor
p53. It is estimated that p53 is abnormal in 50 to 75 % of
colorectal cancer cases, and that this change marks the
transition from noninvasive to invasive disease [16, 17].
Thus, treatments, which act independent of p53 status,
are desirable.
Sulindac, a nonsteroidal anti-inflammatory drug has
shown promising results in treatment of colon cancer.
Recently it was shown to induce SMAC (a mitochondrial
apoptogenic protein)-dependent apoptosis in cells with
nuclear β-catenin (an indicator of colon CSCs) and de-
crease polyp numbers in the APCMin/+ mouse that is
highly susceptible to spontaneous intestinal adenoma
formation [18]. Chemotherapeutic drugs like sulindac
are effective against certain types of cancers but can also
have unexpected adverse effects such as gastrointestinal
bleeding, hepatotoxicity [19, 20] and in some cases
chronic inflammation promoted colon cancer [21]. This
has stimulated active pursuit of new approaches and/or
combination strategies for cancer chemoprevention.
Based on our preliminary data, we hypothesized that the
combination of RSV and GSE suppresses proliferation
and induces apoptosis in colon CSCs. Azoxymethane
(AOM), a DNA alkylating agent, induced mouse colon
cancer model is a well-established and reproducible model
of sporadic colon carcinogenesis to predict chemopreven-
tive efficacy [22]. Intraperitoneal injection of AOM in A/J
mice, a breed that is susceptible to chemically-induced
carcinogenesis, for six weeks resulted in tumor formation
within six weeks of the last injection [23]. Thus, we deter-
mined the efficacy of the RSV-GSE combination using A/J
mice with six week AOM injection regimen and compared
its effects to those of sulindac. Furthermore, we examined
the possible molecular mechanisms that underlie the anti-
cancer activity of RSV-GSE (and compared to sulindac)
using colon CSCs, positive for CD 44, CD 133 and




Grape seed extract (GSE, ORAC value 9000–13,000
μmole Trolox equivalents/g, total phenolic content >
85 % gallic acid equivalents) was a generous gift from
San Joaquin Valley Concentrates (Fresno, CA). We had
previously characterized the GSE used in this study
using UPLC-MS and we detected presence of (+)-catechin
and (−)-epicatechin monomers and their oligomers, and
their gallate derivatives similar to other published papers
[24, 25]. The GSE used in this study lacks resveratrol
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(RSV) as described earlier [10]. BrdU Cell Proliferation
Assay Kit was obtained from Cell Signaling Technology
(Danvers, MA). Antibodies for PARP and cleaved PARP,
p53, pGSK3β, Bax, Bcl-2, β-actin, β-catenin, cyclin D1, c-
Myc, COX-2 and topoisomerase-2β (Topo ii b) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cytochrome C was obtained from Cell Signaling Technol-
ogy (Beverly, MA). All other chemicals including RSV
were obtained from Sigma (St. Louis, MO).
Animal study
A/J male mice (six weeks old; n = 13 per group) pur-
chased from the Jackson Laboratories (Bar Harbor, ME)
were housed in stainless steel wire cages (three or four
per cage) with a 12 h light/dark cycle. Mice were allowed
access to laboratory rodent chow and water ad libitum.
After two weeks of acclimatization, all mice were ran-
domly assigned to four groups and fed AIN-93G diets
obtained from Harlan Laboratories (Indianapolis, IN).
Azoxymethane carcinogen injection
All mice except saline controls received six weekly sub-
cutaneous injections of azoxymethane (AOM, Sigma) in
saline for colon carcinogenesis at 5 mg/kg starting at eight
weeks of age.
Experimental diets
At 16 weeks of age i.e., two weeks following the last
AOM injection, the animals were assigned to the follow-
ing diets – AIN-93G control, AIN-93G supplemented
with RSV-GSE (0.03 and 0.12 % w/w, respectively) or
AIN-93G supplemented with sulindac (0.06 % w/w).
RSV and GSE concentrations were chosen based on the
earlier human (n = 32) study that showed a decrease in
serum oxidative stress markers in obese subjects orally
supplemented with RSV and GSE separately [26]. Sulin-
dac concentration was chosen based on previous clinical
trial study in humans (n = 12) with familial adenomatous
polyposis where administration of sulindac resulted in
significant reduction of polyp number [27]. The saline
control animals received AIN-93G control diets. All ani-
mals had free access to food and water.
Colon tissue collection
After one week of dietary intervention, five animals
from each group were euthanized using isoflurane.
The remaining animals (n = 8/group) were euthanized
after four weeks of dietary intervention. The colon was
resected and washed with RNAse free PBS and observed
under a dissection microscope for counting tumors.
Tumor number was recorded for each animal. At the end
of the study the tumor number was averaged for each
treatment group and represented as means ± S.D. For im-
munohistochemistry and immunofluorescence analysis,
about 1 cm of the colon tissue was collected and fixed
with 10 % buffered formalin. Specimens were then
paraffin-embedded and orthogonally sectioned. The tissue




Prior to staining, the paraffin was softened and the tissue
specimens fixed additionally by baking the slides in an
oven at 55 °C for 20 min. Deparaffinization was per-
formed with Fisherbrand (Pittsburg, PA) clearing agent
citrisolv twice for five minutes and hydrated with de-
creasing concentrations of ethanol (100-100-95-70 v/v).
For target retrieval, the slides were incubated in citrate
buffer at pH 6 (9 mM citrate, 1 mM citric acid) at 95 °C
for 20 min. To quench auto fluorescence from formalin
residues, slides were pretreated with sodium borohydride
(1 mg/mL) for five minutes. Mouse sections were
blocked with mouse IgG serum from the M.O.M kit and
avidin/biotin obtained from Vector Labs (Burlingame,
CA) as per the manufacturer’s protocol.
β-catenin staining
β-catenin staining was performed at 4 °C overnight using
a Abcam rabbit anti-β-catenin antibody (Cambridge,
MA). Biotinylated secondary antibody in combination
with streptavidin fluorescein (Vector Labs) was used for
visualization. Mounting media with DAPI (Vector Labs)
was used as a counterstain. All images were taken in
Olympus BX-63 microscope with the help of Cell Sens
software from Olympus America (Center Valley, PA).
TUNEL staining
TUNEL staining was performed using a cell death detec-
tion kit from Roche Diagnostics (Indianapolis, IN) ac-
cording to the manufacturer’s protocol for formalin
fixed paraffin embedded tissues.
Cancer stem cells
Isolated human colon CSCs positive for cancer stem cell
markers CD133, CD44, CD34, aldehyde dehydrogenase,
telomerase, Sox2, cKit, and Lin28, were obtained from
Celprogen Inc. (San Pedro, CA). To maintain the cells in
their undifferentiated state, colon CSCs maintenance
media and specially coated cell culture flasks obtained
from Celprogen were used. Cells were maintained in
incubation at 37 °C and 5 % CO2. Cell cultures at ap-
proximately 80 % confluence were used for all in
vitro experimental procedures. For all experiments low
passage number (less than 10) cells were used (not more
than three weeks after resuscitation). The authentica-
tion information for the cell line obtained from Cel-
progen is available under supplemental information.
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Lentiviral shRNA-mediated attenuation of p53 in colon CSCs
Lentiviral particles encoding shRNA targeting p53 obtained
from Santa Cruz Biotechnology were used to attenuate p53
expression in colon CSCs as described earlier [28].
Cell proliferation
Cell viability was assessed by BrdU (5-bromo-2′-deoxyuri-
dine) assay kit from Cell Signaling Technology (Danvers,
MA). Briefly, cells were plated at a density of 1 × 105 per
well in 12-well plates. Media was replaced after 24 h with
serum-free colon CSCs media (Celprogen) and dosed with
RSV-GSE and/or sulindac. For all in vitro experiments
sulindac sulfide, the active form of sulindac was used. Pre-
liminary experiments revealed that lower concentrations
of RSV-GSE were potent in suppressing proliferation of
colon CSCs compared to the concentrations used in our
earlier study using HCT-116 early colon cancer cells [10].
Interestingly, other researchers also showed that dietary
bioactive compounds are more potent against highly
proliferating or advanced cancer cells that are distinctly
different from normal cells [29]. Hence, for this study
doses of RSV were kept constant at 9 μM, whereas GSE
doses in the combination varied (6.25, 12.5 and 25 μg/mL).
Sulindac was dosed at 6.25, 12.5 and 25 μg/mL. After 24 h,
BrdU incorporation was assayed as described in manufac-
turer’s protocol. The experiment was carried out in tripli-
cate, and results were expressed as the means ± S.E.
TUNEL assay
Apoptosis was quantified by using fluorescein labeled
nucleotide and terminal deoxynucleotidyl transferase
(TdT) to identify DNA fragmentation (characteristic of
apoptosis). Briefly, cells (9 × 104) were seeded in four-
chambered glass slides, and after treatment with RSV-
GSE or sulindac for 12 h, the in situ cell death detection
kit from Roche Diagnostics was used for quantifying
apoptosis based on the manufacturer protocol. The ex-
periment was carried out in triplicate, and results were
expressed as means ± S.E.
Sphere formation assay
Briefly, colon CSCs (10,000 cells per well) were cultured
in stem cell specific serum free media in an ultra-low at-
tachment six-well plates. The cells were maintained in
similar conditions as mentioned earlier under the cancer
stem cells section. RSV-GSE or sulindac was added six
hours after the cells were added to the six-well plates. At
the end of ten days, the number of spheres was assayed
using a phase contrast microscope.
Western blot
Cells were plated in six-well plates at a concentration of
3.0 × 105 cells per well in colon CSCs media. After 24 h,
cells were transferred to serum free medium for 18 h.
Protein was extracted according to our previously pub-
lished protocols [10, 30]. The blots were incubated with
primary antibodies overnight at 4 °C at a dilution of
1:500. Subsequently, the blots were incubated with sec-
ondary antibodies for two hours at room temperature at
a dilution of 1:10,000. Blots were imaged and quantified
using the Odyssey infrared imaging system and software
(Lincoln, NE) and normalized to β-actin, a loading con-
trol for cytoplasmic proteins and topoisomerase-2β as a
loading control for nuclear proteins. Each treatment was
carried out in triplicate, and results were expressed as
means ± S.E.
Statistical analysis
Data are expressed as means ± S.E. for all the data.
Significance was determined by one-way ANOVA with
post hoc Tukey analysis for in vitro data (SPSS v21, IBM,
Armonk, NY). For animal studies, analysis of data was
done using mixed procedure in SAS v9.4 software
(Cary, NC). The p values < 0.05 were considered sta-
tistically significant.
Results
RSV-GSE suppressed AOM-induced tumor incidence in
mice
Mice exposed to AOM developed colon tumors at the
end of the study. The incidence of AOM-induced tu-
mors was suppressed in the RSV-GSE group by over
50 % (Fig. 1a), an effect similar to that of sulindac. Sulin-
dac treatment resulted in significant gastrointestinal tox-
icity (stomach/intestinal ulcers) marked with loss of fat
deposits (Fig. 1b). Such toxicity was not observed in the
animals consuming RSV-GSE. Neither RSV-GSE nor
sulindac significantly affected average weight gain or
food intake across the groups.
RSV-GSE induced apoptosis and reduced number of
crypts with colon cancer stem cells
Previously conducted studies determined a one week
time window for analyzing sulindac-induced apoptosis in
intestinal stem cells in APCMin/+ mice because of the
rapid and transient nature of apoptotic events. Here we
found that RSV-GSE supplementation for one week in-
duced apoptosis with 18 % of crypts containing at least
one TUNEL-positive cell, an effect comparable to the
18.5 % in mice receiving sulindac (Fig. 2a). In addition,
RSV-GSE and sulindac treatment for one week also re-
duced the number of crypts containing cells with nu-
clear β-catenin (an indicator of colon CSCs) by more
than 50 % (Fig. 2b, c). These data demonstrate that in-
testinal stem cells with nuclear β-catenin (CSCs) may be
targeted for apoptosis induction following RSV-GSE or
sulindac treatment in mice with AOM induced colon
carcinogenesis. This might also explain lower tumor
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incidence in the RSV-GSE and sulindac groups at the
end of the study (Fig. 1a).
RSV-GSE suppressed proliferation and induced apoptosis
in colon cancer stem cells
Proliferation and apoptotic response were determined in
isolated human colon CSCs in response to RSV-GSE or
sulindac treatment using BrdU incorporation and
TUNEL, respectively. Both RSV-GSE and sulindac in-
duced dose-dependent suppression of cell proliferation
(Fig. 3a) and elevated apoptosis (Fig. 3b, c) in colon
CSCs. The IC(50) values for RSV-GSE was determined
to be 9 μM and 12.5 μg/mL respectively, and for sulin-
dac at 12.5 μg/mL which are at physiologically relevant
doses. Thus, we used these doses for subsequent experi-
ments to determine the mechanism of action.
RSV-GSE suppressed sphere formation ability of colon CSCs
To assess RSV-GSE ability to target the self-renewal cap-
ability of CSCs, sphere formation assay was used (Fig. 3d).
Figure 3d shows representative images collected from the
sphere formation assay and demonstrate the decreased
number of spheres associated with the treatments in com-
parison to the control. RSV-GSE treatment completely
suppressed colon CSCs sphere formation. This demon-
strates that, in addition to the anti-proliferative and
pro-apoptotic activities, RSV-GSE alters the stem-like
properties by inhibiting colon cancer stem cell self-renewal
as measured using the sphere formation assay.
RSV-GSE suppressed Wnt pathway proteins
As the Wnt/β-catenin signaling pathway is critical for
stem cell fate, we treated colon CSCs with RSV-GSE or
sulindac and measured proteins in the pathway - pGSK3β
(cytoplasmic) and, β-catenin, c-Myc and cyclin D1 (all nu-
clear) using western blotting. Both RSV-GSE and sulindac
treatment suppressed protein levels of pGSK3β in the
cytoplasm and nuclear levels of β-catenin. This indicates
reduced translocation of β-catenin to the nucleus and thus
suppression of the canonical Wnt/β-catenin signaling that
is frequently deregulated in colon cancer (Fig. 4a, b).
Downstream proteins of β-catenin, c-Myc and cyclin D1,
Fig. 1 RSV – GSE suppressed tumor incidence in the colon similar to that of sulindac. a Mice injected with AOM consumed control, RSV-GSE or
sulindac (positive control) supplemented diet for four weeks and were euthanized. Whole colon tissue was resected and observed under a
dissection microscope for visible tumors. SU = Sulindac; RG = RSV-GSE. Values are in means ± S.E. (n = 8 in each group). Means that differ by a
common letter (a, b) differ at p < 0.05. b Short-term feeding of sulindac resulted in stomach ulcers (hyperplasia of the stomach, black arrows) and
loss of adipose tissue deposits (blue arrows) compared to control. RSV-GSE supplemented diet consuming animals showed neither hyperplasia
nor loss of adipose tissue deposits
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critical in stem cell proliferation, were also suppressed by
RSV-GSE treatment. However, sulindac treatment failed
to induce any changes in c-Myc and cyclin D1 levels
(Fig. 4c, d).
RSV-GSE elevated mitochondrial apoptotic pathway
proteins
P53 is a critical transcription factor that controls cell fate
in response to various stresses. In addition, as “the
guardian of the genome”, p53 protein plays a critical role
in tumor suppression by inducing growth arrest, apop-
tosis, and senescence, as well as by blocking angiogen-
esis. Nuclear levels of p53 were elevated by RSV-GSE
treatment, but not sulindac, compared to control in
colon CSCs (Fig. 4e). Downstream of p53, Bax, the pro-
apoptotic protein was elevated and Bcl-2, the anti-
apoptotic protein, was suppressed by RSV-GSE treat-
ment indicating mitochondrial-mediated apoptosis. Bax/
Bcl-2 ratio was elevated only in the RSV-GSE group but
not sulindac compared to the control (Fig. 4g) in colon
CSCs. Data for cleaved PARP, indicator of apoptosis,
mirrored the Bax/Bcl-2 ratio, with RSV-GSE treatment
showing highest levels of cleaved PARP (Fig. 4f ).
RSV-GSE efficacy is retained even in the absence of p53
To determine the requirement of p53 in the CSC inhibi-
tory effects of RSV-GSE, we used a lentiviral p53-shRNA
construct to attenuate p53 expression. Reduced p53 ex-
pression had no effect on RSV-GSE-mediated suppres-
sion of nuclear levels of β-catenin and its downstream
proteins, c-Myc and cyclin D1 (Fig. 5a–c). RSV-GSE also
induced apoptosis in colon CSCs as measured using
PARP cleavage (Fig. 5d) and increased cytochrome C ex-
pression greater than that of sulindac (Fig. 5e). These re-
sults indicate that GSE-RSV-induced CSC apoptosis
occurs via a p53-independent mechanism. Similar trend
was observed in nuclear levels of COX-2 in both colon
CSCs and colon CSCs with shRNA attenuated p53 –
RSV-GSE treatment was more potent in suppressing
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Fig. 2 RSV – GSE treatment induced apoptosis and reduced the number of crypts containing cells with nuclear β-catenin (an indicator of colon CSCs).
Mice injected with AOM were fed with control, RSV-GSE or sulindac-containing diet for one week. Distal colon sections from the mice were analyzed
for TUNEL positive crypts and β-catenin localization by immunofluorescence. a The fractions of crypts containing at least one TUNEL-positive cell
(indicator of apoptotic cells) were determined. b Quantification of crypts with nuclear β-catenin in mice treated with control, RSV-GSE or sulindac
supplemented diet for one week. Accumulation of nuclear β-catenin is hallmark of cancer stem cells and hence was used as an indirect measure for
evaluating elimination of cancer stem cells. c Staining of β-catenin and DAPI (blue) in mice treated with AOM. Circles mark representative colon stem
cells with nuclear β-catenin (CSCs). SU = Sulindac; RG = RSV-GSE. Values are in means ± S.E. (n = 5 in each group). At least 300 crypts from each animal
were analyzed. Means that differ by a common letter (a, b, c) differ at p < 0.05. (Scale bars: 15 μm)








































































































































Fig. 3 RSV – GSE suppressed proliferation, induced apoptosis and suppressed sphere formation in colon CSCs similar to that of sulindac.
a Anti-proliferative effect of RSV-GSE in colon CSCs. RSV-GSE induced apoptosis in CSCs (b, c) similar to that of sulindac. CSCs were treated with
sulindac (6.25, 12.5 and 25 μg/mL) or RSV-GSE (RSV - 9 μM and GSE 6.25, 12.5 and 25 μg/mL) for 24 h and BrdU assay was performed to
assess proliferation. TUNEL assay was performed based on manufacturer protocol (Roche) and the results are expressed as per cent apoptosis. Cells
fluorescing bright green due to fragmented DNA indicate apoptotic cells. Pictures taken on fluorescence microscope at 20× magnification.
Representative pictures are shown for Control, RSV-GSE at 9 μM and 12.5 μg/mL respectively and sulindac at 12.5 μg/mL. d-e, Sphere formation was
assessed as described in methods. Representative images taken from the sphere formation assay are presented. Results were expressed as mean ± S.E.
for three experiments at each time point. Means that differ by a common letter (a, b, c, d, e, f) differ at p < 0.05
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Discussion
The objective of present study was to evaluate the anti-
cancer efficacy of RSV-GSE in a mouse model of colon
cancer, and to determine the mechanisms of action using
human colon CSCs in vitro. Our results present the first
evidence of in vivo anti-colon cancer efficacy of a com-
bination of the grape bioactive components RSV and
GSE in the mouse model with AOM-induced colon car-
cinogenesis. Our data in vitro in colon CSCs demon-
strate suppression of nuclear translocation of β-catenin
(Wnt/β-catenin signaling pathway) and induction of
mitochondrial-mediated apoptosis.
Our results indicate that RSV-GSE, bioactive compo-
nents from grapes, suppress tumor incidence in a mouse
model with AOM-induced colon carcinogenesis (Fig. 1a).
Furthermore, RSV-GSE consumption had reduced tox-
icity compared to sulindac, suggesting specific targeting
of cancer cells (Fig. 1b). Indeed, clinical trials in humans
have shown that RSV is quite safe [31], similar results
have been observed for GSE [32].
Accumulated experimental evidence has suggested
that most cancers, including colon cancer, have a hierar-
chal organization regulated by a small number of self-
renewing cancer cells, called CSCs [33]. CSCs including
colon CSCs have shown to be resistant to conventional
chemotherapeutic regimens that target homogeneous
populations of rapidly proliferating differentiated tumor
cells. For e.g., CD133-positive colon CSCs were shown to
be resistant to the conventional cytotoxic drug 5-
florouracil and the resistance was shown to be dependent
on Wnt signaling [34]. The proliferation and the acquisi-
tion of the stem cell fates is coordinated by a small num-
ber of highly evolutionarily conserved signaling pathways,
including the Wnt/β-catenin signaling pathway, which is
commonly deregulated in most colon cancers [35]. Nu-
clear accumulation of β-catenin is implicated in the trans-
formation of stem cells to oncogenic stem cells in the
colon [15]. Although, it has been observed that nuclear β-
catenin accumulation is also seen in normal colonic stem
cells and progenitor cells which are located at the bottom
proliferative compartment of the intestinal crypts [36, 37],
a recent study has shown that it is observed in less than
0.01 % of crypts in wild-type mice [18]. Hence, we [38]
and others [18] considered increased number of crypts
with colonic stem cells with nuclear β-catenin accumu-
lation (Additional file 1: Figure S1) as a hallmark of
colon carcinogenesis and a signature feature of elevated
oncogenic stem cells. Qiu et al. reported that one week
of sulindac treatment resulted in a 75 % reduction in

















































































































































































































































Fig. 4 a–d, RSV – GSE suppressed levels of proteins involved in Wnt/β-catenin pathway in colon CSCs with functioning p53. Nuclear β-catenin
(a) and its regulator phosphorylated GSK3β (b) levels were suppressed by RSV-GSE similar to that of sulindac. Downstream targets of Wnt/β-catenin
pathway – c-Myc (c) and Cyclin D1 (d), in the nucleus were suppressed by RSV-GSE compared to sulindac. E-G, RSV-GSE induced apoptosis via p53
dependent pathway in colon cancer stem cells (CSCs) with functioning p53. Nuclear p53 levels were elevated (e) by RSV-GSE but not sulindac.
Cleaved PARP (f) and Bax/Bcl-2 ratio (g) were also elevated by RSV-GSE but not sulindac. Colon CSCs were treated with RSV-GSE at 9 μM and
12.5 μg/mL, or sulindac at 12.5 μg/mL for 24 h, and cytosolic and nuclear cell lysates were analyzed for respective proteins by western blotting.
Actin and topoisomerase-2β (Topo II b) were used as loading controls for cytosolic and nuclear proteins respectively. Values are in means ± S.E. Means
that differ by a common letter (a, b, c, or x, y, z) differ at p < 0.05
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catenin. Most importantly, a vast majority (98 %) of identi-
fiable stem cells with accumulated nuclear β-catenin in
sulindac-treated APCMin/+ mice were TUNEL-positive
at this time point [18]. In the current study, where
AOM (a well-known colon specific carcinogen) was
used to induce colon carcinogenesis, RSV-GSE consuming
animals had 62 % reduction in number of crypts contain-
ing cells that have accumulated nuclear β-catenin (Fig. 2a).
Additionally, our data suggest that this could be due to in-
duction of apoptosis (Fig. 2b). Efficacy of RSV-GSE was
Fig. 5 Modulation of Wnt/β-catenin and apoptotic signaling proteins by RSV – GSE in colon CSCs with attenuated p53. β-catenin (a) and its
downstream targets c-Myc (b) and cyclin D1 (c) were suppressed by RSV-GSE compared to sulindac. Pro-apoptotic proteins cleaved PARP (d) and
cytochrome C (e) levels were elevated by RSV-GSE greater than that of control and sulindac. Colon CSCs were treated with RSV-GSE at 9 μM and
12.5 μg/mL, or sulindac at 12.5 μg/mL for 24 h, and cytosolic and nuclear cell lysates were analyzed. Actin and topoisomerase-2β (Topo II b) were
used as loading controls for cytosolic and nuclear proteins respectively. C = Control; SU = Sulindac; RG = RSV-GSE. Values are in means ± S.E. Means
that differ by a common letter (a, b, c, or x, y, z) differ p < 0.05
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comparable or better than sulindac. The in vivo data was
supported by our in vitro observations where we noticed
that RSV-GSE at physiologically relevant doses suppressed
proliferation and induced apoptosis as well as suppressed
sphere formation in colon CSCs (Fig. 3a–d).
There is evidence that nuclear accumulation of β-
catenin results in accelerated tumor cell proliferation
and tumor progression through the transcriptional acti-
vation of target genes including c-Myc, cyclin D1 and
COX-2 [39]. Mechanistic data in vitro confirmed our in
vivo observations as RSV-GSE suppressed nuclear β-
catenin accumulation in colon CSCs (Fig. 4a). RSV-GSE
also suppressed cytoplasmic levels of pGSK3β (Fig. 4b)
shown to induce nuclear β-catenin translocation and
down-regulated nuclear levels of proteins downstream of
Wnt/β-catenin pathway, c-Myc and cyclin D1 (Fig. 4c, d).
c-Myc and cyclin D1 are the key signatory genes of
Wnt signaling and both function in the stimulation of
cell proliferation and in preventing apoptosis. Coordin-
ation of c-Myc with cyclin D1 or its upstream activators
not only accelerates tumor formation, but also may
drive tumor progression to a more aggressive pheno-
type [40]. Although, previously published research has
shown that RSV and GSE suppressed nuclear β-catenin
translocation, to our knowledge, this is the first study
to show such an effect in colon CSCs.
Alterations in Wnt/β-catenin signaling might also ex-
plain why RSV-GSE also suppressed sphere formation
ability in vitro (Fig. 3d). Because c-Myc and cyclin D1 also
play a role in stemness [41], our data showing suppressed
c-Myc and cyclin D1 only by RSV-GSE treatment might
explain its higher potency compared to sulindac. Our data
is in line with recent research showing that dietary com-
pounds including grape seed extract, curcumin, lycopene
and resveratrol are promising chemopreventive agents
against various types of cancers owing to their direct and
indirect effects on CSC self-renewal pathways, such as
Wnt/β-catenin signaling pathway [42–45].
P53 plays a critical role in tumor suppression by in-
ducing growth arrest, apoptosis, and senescence, as
well as by blocking angiogenesis. Consistent with the role
of p53 as a cell stress-associated transcription factor
[46, 47], we observed increased expression of p53 (Fig. 4e)
and p53-responsive Bax (and Bax/Bcl-2 ratio) (Fig. 4g) in
colon CSCs with RSV-GSE treatment. This indicates
RSV-GSE induced intrinsic apoptotic signaling pathway by
Bax-induced increased permeation of mitochondrial mem-
brane, resulting in release of cytochrome C and activation
of caspases. Whether similar pathway of apoptosis is acti-
vated in p53 knockout cells remains to be seen, although
cytochrome C was elevated by RSV-GSE treatment in colon
CSCs with shRNA attenuated p53. Mutational inactivation
of p53 is one of the most frequent events found in over
50–75 % of colon cancer cases, and marks transition to
metastasis [17, 48–50]. Our results showing that RSV-
GSE exerts its biological efficacy, both anti-proliferative
and pro-apoptotic, in colon CSCs independent of their
p53 status (Fig. 5a–e) confers an advantage to the use of
RSV-GSE for primary and secondary chemoprevention.
Preclinical and clinical studies suggest that COX-2 is
involved in chronic inflammation and its activation may
be involved in inflammation-mediated stem cell prolifer-
ation/differentiation [51]. Our data suggests that RSV-
GSE was more effective compared to sulindac in sup-
pressing nuclear COX-2 levels (Fig. 6a, b) in colon CSCs
and colon CSCs with shRNA attenuated p53 and might
further explain higher potency of RSV-GSE combination
compared to sulindac. Further, NSAIDs like sulindac can
suppress both COX-1 and COX-2 thereby deplete pros-
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Fig. 6 RSV – GSE suppressed COX-2 levels in colon CSCs with functioning (a) and attenuated p53 (b). Colon CSCs were treated with RSV-GSE at
9 μM and 12.5 μg/mL respectively or sulindac at 12.5 μg/ml for 24 h, and nuclear cell lysates were analyzed for COX-2 levels by western blotting.
Topoisomerase-2β (Topo II b) was used as a loading control. C = Control; SU = Sulindac; RG = RSV-GSE. Values are in means ± S.E. Means that differ
by a common letter (a, b, c) differ at p < 0.05
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production, mucus secretion, and maintenance of blood
flow [52] and thus mucosal healing [53]. This explains
the increased gastrointestinal toxicity (stomach ulcers
and loss of adipose tissue deposits) in mice fed with
sulindac. Unlike, sulindac, RSV and GSE (proanthocyani-
dins) have minimal effects on COX-1/PGE2 [54] and
thus explains the lack of stomach ulcers and adipose tis-
sue loss. Thus, in the future studies, it is critical to ex-
plore whether sulindac eliminates normal colon stem
cells along with colon cancer stem cells whereas RSV-
GSE is selective against only colon cancer stem cells.
This aspect could not be assessed in the current study,
as we did not include normal control animals consuming
RSV-GSE or sulindac.
Conclusion
Our study has shown that RSV-GSE combination elimi-
nates colon CSCs in vivo and in vitro similar to that of
NSAID sulindac without any toxicity. Our results also
establish the molecular basis for the beneficial effect of
RSV-GSE combination that is a popular dietary supple-
ment. Although further investigations are needed to
understand more on the interactions of these agents and
on long-term colon cancer chemopreventive or chemo-
therapeutic potential of the RSV-GSE, our findings sug-
gest that clinical testing of RSV-GSE against colon
cancer is required.
Additional file
Additional file 1: Figure S1. Nuclear β-catenin localization is observed
in stem cells. Co-localization of Lgr5 (green) and β-catenin (red) in mice
treated with AOM. DAPI (blue) is the nuclear counterstain (panel a). Panel
b shows Lgr5 positive stem cell (green) at the crypt base. Panel c shows
β-catenin staining around the nucleus except at the crypt base. Panel d
merged image confirms co-localization of Lgr5 and nuclear β-catenin
only in oncogenic colon stem cells. Circles mark representative cell with
Lgr5 and nuclear β-catenin. Scale bars: 20 μm. Formalin fixed paraffin
embedded sections from three animals were analyzed and representative
image(s) are shown. (PPTX 1934 kb)
Abbreviations
AOM, azoxymethane; CSC, cancer stem cells; GSE, Grape seed extract; RSV,
Resveratrol
Acknowledgments
We would like to thank members of Laboratory Animal Resources at
Colorado State University for their assistance with mice study. We would like
to thank San Joaquin Valley Concentrates (Fresno, CA) for supplying GSE
powder. We would also like to thank Laura Markham for her assistance in
collecting colon tissues and Abigail Sido for her help with editing the
manuscript.
Funding
Dr. Jairam KP Vanamala is the PI of the National Research Interest Integrated
Grant 2009-55200-05197 from United States Department of Agriculture
(USDA)-National Institute of Food and Agriculture (NIFA) that supported the
work presented in this manuscript. Dr. Lavanya Reddivari is the PI of the
grant 2016-67017-24512 from USDA-NIFA that also supported the work
presented in this manuscript.
Availability of data and materials
The authors would like to state that all relevant raw data would be made
available to any scientist upon request, without breaching participant
confidentiality.
Authors’ contributions
LR and VC performed the in vivo study. VC carried out all the in vivo
experiments and drafted the manuscript. LR, VR, SR and JV participated in
collecting tissue samples at the end of the study. VR carried out the in vitro
assays. SR drafted the manuscript. RE and JD edited and helped in shaping
of the manuscript. LR and JV conceived the study, and participated in its
design. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All the authors listed in this manuscript have read and approved the final
version for publication.
Ethics approval and consent to participate
All experimental procedures on the animals were approved by the
Institutional Animal Care and Use Committee at Colorado State University.
Author details
1Department of Plant Science, The Pennsylvania State University, University
Park, PA 16802, USA. 2Department of Food Science, The Pennsylvania State
University, 326 Food Science Building, University Park, PA 16803, USA. 3The
Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State
University, University Park, PA 16802, USA. 4The Pennsylvania State Hershey
Cancer Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA
17033, USA. 5Center for Molecular Immunology and Infectious Diseases, The
Pennsylvania State University, University Park, PA 16802, USA. 6Department of
Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa, Andhra
Pradesh 516216, India.
Received: 21 July 2016 Accepted: 29 July 2016
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin.
2014;64(1):9–29.
2. Marshall JR. Prevention of colorectal cancer: diet, chemoprevention, and
lifestyle. Gastroenterol Clin North Am. 2008;37(1):73–82. vi.
3. Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal
cancer: the possible role of insulin resistance. Nutr Cancer. 2000;37(1):19–26.
4. Cappellani A, Zanghi A, Di Vita M, Cavallaro A, Piccolo G, Veroux P, Lo Menzo E,
Cavallaro V, de Paoli P, Veroux M, et al. Strong correlation between diet and
development of colorectal cancer. Front Biosci (Landmark Ed). 2013;18:190–8.
5. Liu RH. Dietary bioactive compounds and their health implications. J Food
Sci. 2013;78(s1):A18–25.
6. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent
studies to clinical trials. Cancer Prev Res. 2009;2(5):409–18.
7. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses
IGF-1 induced human colon cancer cell proliferation and elevates apoptosis
via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.
BMC Cancer. 2010;10(1):238.
8. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic
death of human prostate carcinoma DU145 cells via caspases activation
accompanied by dissipation of mitochondrial membrane potential and
cytochrome c release. Am J Potato Res. 2002;23(11):1869–76.
9. Dinicola S, Cucina A, Pasqualato A, D’Anselmi F, Proietti S, Lisi E, Pasqua G,
Antonacci D, Bizzarri M. Antiproliferative and apoptotic effects triggered by
Grape Seed Extract (GSE) versus epigallocatechin and procyanidins on colon
cancer cell lines. Int J Mol Sci. 2012;13(1):651–64.
10. Radhakrishnan S, Reddivari L, Sclafani R, Das UN, Vanamala J. Resveratrol
potentiates grape seed extract induced human colon cancer cell apoptosis.
Front Biosci (Elite Ed). 2011;3:1509–23.
11. Sharma G, Tyagi AK, Singh RP, Chan DC, Agarwal R. Synergistic anti-cancer
effects of grape seed extract and conventional cytotoxic agent doxorubicin
against human breast carcinoma cells. Breast Cancer Res Treat. 2004;85(1):1–12.
Reddivari et al. BMC Complementary and Alternative Medicine  (2016) 16:278 Page 11 of 12
12. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of
colorectal cancer stem cells. Oncotarget. 2010;1(6):387–95.
13. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den
Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as
the cells-of-origin of intestinal cancer. Nature. 2009;457(7229):608–11.
14. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells:
promise of targeted therapy. Gastroenterology. 2010;138(6):2151–62.
15. Schepers A, Clevers H. Wnt signaling, stem cells, and cancer of the
gastrointestinal tract. Cold Spring Harb Perspect Biol. 2012;4(4):a007989.
16. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher
HI, Ludwig T, Gerald W, et al. Crucial role of p53-dependent cellular
senescence in suppression of Pten-deficient tumorigenesis. Nature.
2005;436(7051):725–30.
17. Bedeir A, Krasinskas AM. Molecular diagnostics of colorectal cancer. Arch
Pathol Lab Med. 2011;135(5):578–87.
18. Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H, Oue N, Yasui W,
Clevers H, Schoen RE, et al. Chemoprevention by nonsteroidal anti-
inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-
dependent apoptosis. Proc Natl Acad Sci U S A. 2010;107(46):20027–32.
19. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs
(NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm
Sci. 2008;11(2):81s–110.
20. Narsinghani T, Sharma R. Lead optimization on conventional non‐steroidal
anti‐inflammatory drugs: an approach to reduce gastrointestinal toxicity.
Chem Biol Drug Des. 2014;84(1):1–23.
21. Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, Pickford R, Currey N,
Musgrove EA, Kohonen-Corish MR. The NSAID sulindac is chemopreventive
in the mouse distal colon but carcinogenic in the proximal colon. Gut.
2010;60(3):350–60. doi:10.1136/gut.2010.208314.
22. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in
predicting efficacy in humans? A systematic review and meta-analysis
of colon chemoprevention in rats, mice and men. Eur J Cancer.
2005;41(13):1911–22.
23. Ilsley JN, Belinsky GS, Guda K, Zhang Q, Huang X, Blumberg JB, Milbury PE,
Roberts Ii LJ, Stevens RG, Rosenberg DW. Dietary iron promotes
azoxymethane-induced colon tumors in mice. Nutr Cancer. 2004;49(2):162–9.
24. Weber HA, Hodges AE, Guthrie JR, O’Brien BM, Robaugh D, Clark AP, Harris
RK, Algaier JW, Smith CS. Comparison of proanthocyanidins in commercial
antioxidants: grape seed and pine bark extracts. J Agric Food Chem.
2007;55(1):148–56.
25. Agarwal C, Veluri R, Kaur M, Chou SC, Thompson JA, Agarwal R.
Fractionation of high molecular weight tannins in grape seed extract and
identification of procyanidin B2-3,3′-di-O-gallate as a major active
constituent causing growth inhibition and apoptotic death of DU145
human prostate carcinoma cells. Carcinogenesis. 2007;28(7):1478–84.
26. De Groote D, Van Belleghem K, Devière J, Van Brussel W, Mukaneza A,
Amininejad L. Effect of the intake of resveratrol, resveratrol phosphate, and
catechin-rich grape seed extract on markers of oxidative stress and gene
expression in adult obese subjects. Ann Nutr Metab. 2012;61:15–24.
27. Cruz–Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM.
Gastroenterology. 2002;122(3):641–5.
28. Massey AR, Reddivari L, Vanamala J. The Dermal layer of sweet sorghum
(Sorghum bicolor) stalk, a byproduct of biofuel production and source of
unique 3-deoxyanthocyanidins, has more antiproliferative and proapoptotic
activity than the pith in p53 variants of HCT116 and colon cancer stem
cells. J Agric Food Chem. 2014;62(14):3150–9.
29. Madiwale GP, Reddivari L, Stone M, Holm DG, Vanamala J. Combined effects
of storage and processing on the bioactive compounds and pro-apoptotic
properties of color-fleshed potatoes in human colon cancer cells. J Agric
Food Chem. 2012;60(44):11088–96.
30. Vanamala J, Glagolenko A, Yang P, Carroll RJ, Murphy ME, Newman RA, Ford
JR, Braby LA, Chapkin RS, Turner ND, Lupton JR. Dietary fish oil and pectin
enhance colonocyte apoptosis in part through suppression of PPAR{delta}/
PGE2 and elevation of PGE3. Carcinogenesis. 2008;29(4):790–96.
31. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP,
Booth TD, Crowell JA, Perloff M, Gescher AJ. Phase I dose escalation
pharmacokinetic study in healthy volunteers of resveratrol, a potential
cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev.
2007;16(6):1246–52.
32. Bentivegna S, Whitney K. Subchronic 3-month oral toxicity study of grape
seed and grape skin extracts. Food Chem Toxicol. 2002;40(12):1731–43.
33. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise
and the potential. Semin Oncol. 2015;42, Supplement 1(0):S3–17.
34. Deng Y, Pu X, Huang M, Xiao J, Zhou J, Lin T, Lin EH. 5-Fluorouracil
upregulates the activity of Wnt signaling pathway in CD133-positive colon
cancer stem-like cells. Chin J Cancer. 2010;29(9):810–5.
35. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and
cancer stem cells. Curr Opin Cell Biol. 2013;25(2):254–64.
36. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt
signaling controls the phosphorylation status of β-catenin. J Biol Chem.
2002;277(20):17901–5.
37. Van De Wetering M, Sancho E, Verweij C, De Lau W, Oving I, Hurlstone A,
Van Der Horn K, Batlle E, Coudreuse D, Haramis A-P. The β-catenin/TCF-4
complex imposes a crypt progenitor phenotype on colorectal cancer cells.
Cell. 2002;111(2):241–50.
38. Charepalli V, Reddivari L, Radhakrishnan S, Vadde R, Agarwal R, Vanamala JK.
Anthocyanin-containing purple-fleshed potatoes suppress colon
tumorigenesis via elimination of colon cancer stem cells. J Nutr Biochem.
2015;26(12):1641–649.
39. Tatsuguchi A, Kishida T, Fujimori S, Tanaka S, Gudis K, Shinji S, Furukawa K,
Tajiri T, Sugisaki Y, Fukuda Y. Differential expression of cyclo‐oxygenase‐2
and nuclear β‐catenin in colorectal cancer tissue. Aliment Pharmacol Ther.
2006;24(s4):153–9.
40. Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, Cyclin
D1, and their interaction in cancer formation, progression, and response to
chemotherapy. Crit Rev Oncog. 2007;13:2.
41. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/β-catenin
pathway regulates growth and maintenance of colonospheres. Mol Cancer.
2010;9(1):212.
42. Velmurugan B, Singh RP, Kaul N, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents intestinal tumorigenesis in APC min/+ mice.
Neoplasia. 2010;12(1):95–102.
43. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of
colon cancer stem-like cells by the combination of curcumin and FOLFOX.
Transl Oncol. 2009;2(4):321–8.
44. Chen B-J, Wu Y-L, Tanaka Y, Zhang W. Small molecules targeting c-Myc
oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014;10(10):1084.
45. Pistollato F, Giampieri F, Battino M. The use of plant-derived bioactive
compounds to target cancer stem cells and modulate tumor
microenvironment. Food Chem Toxicol. 2015;75:58–70.
46. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature.
2000;408(6810):307–10.
47. Hoffman B, Liebermann D. Apoptotic signaling by c-MYC. Oncogene.
2008;27(50):6462–72.
48. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis:
road maps to cancer. World J Gastroenterol. 2007;13(28):3784.
49. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J
Med. 2009;361(25):2449–60.
50. Sarasqueta AF, Forte GI, Corver WE, de Miranda NF, Ruano D, van Eijk R,
Oosting J, Tollenaar RA, van Wezel T, Morreau H. Integral analysis of p53
and its value as prognostic factor in sporadic colon cancer. BMC Cancer.
2013;13(1):277.
51. Thanan R, Murata M, Ma N, Hammam O, Wishahi M, El Leithy T, Hiraku Y,
Oikawa S, Kawanishi S. Nuclear localization of COX-2 in relation to the
expression of stemness markers in urinary bladder cancer. Mediators
Inflamm. 2012;2012:8.
52. Cheung DY, Kim JI, Park S-H, Kim JK. Proanthocyanidin from Grape Seed
Extracts protects indomethacin-induced small intestinal mucosal injury.
Gastroenterol Res Pract. 2014;2014:8.
53. Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection
and ulcer healing in the gastrointestinal tract. Adv Clin Chem. 2010;51:121.
54. Martı́ AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol
found in grapes, suppresses oxidative damage and stimulates
apoptosis during early colonic inflammation in rats. Biochem Pharmacol.
2004;67(7):1399–410.
Reddivari et al. BMC Complementary and Alternative Medicine  (2016) 16:278 Page 12 of 12
